


Description

| | |
|-------------------|---|
| Product Name | GSK1904529A |
| Brief Description | Inhibitors |
| Purification | 98.64% |
| Target Name | IGF-1R inhibitor; Raf inhibitor; Syk inhibitor; VEGFR inhibitor |
| Calculated MW | 851.96 |
| Formulation | C44H47F2N9O5S |
| Storage | 3 years -20°C powder; 2 years -80°C in solvent; |

Images



Product Description

Research

Area: Cancer
 SMILES: CCC1=CC(NC2=NC(=CC=N2)C2=C(N=C3C=CC=CN23)C2=CC(C(=O)NC3=C(F)C=CC=C3F)=C(OC)C=C2)=C(OC)C=C1N1C
 CC(CC1)N1CCN(CC1)S(C)(=O)=O | c:8,10,17,19,30,33,35,42,48,t:2,6,13,15,24,38,44 | Pathways: Angiogenesis; MAPK; Tyrosine
 Kinase/Adaptors Receptor: IGF-1R; Insulin Receptor; B-Raf (V600E); Syk; VEGFR2
 Boiling pt: Melting pt: Solubility: DMSO: 124 mg/mL (145.54 mM) Ethanol:

References

1. Sabbatini P, et al. Clin Cancer Res, 2009, 15(9), 3058-3067.

Note: This product is for in vitro research use only